Products Categories
| CAS No.: | 13523-86-9 |
|---|---|
| Name: | Pindolol |
| Molecular Structure: | |
|
|
|
| Formula: | C14H20N2O2 |
| Molecular Weight: | 248.325 |
| Synonyms: | 2-Propanol,1-(indol-4-yloxy)-3-(isopropylamino)- (8CI);(RS)-Pindolol;(?à)-4-[2-Hydroxy-3-(isopropylamino)propoxy]indole;(?à)-LB 46;(?à)-Pindolol;1-[(1-Methylethyl)amino]-3-(4-indolyloxy)-2-propanol;4-(2-Hydroxy-3-isopropylaminopropoxy)indole;4-(3-Isopropylamino-2-hydroxypropoxy)indole;Apo-pindol;Betapindol;BlocklinL;Calvisken;Carvisken;DL-4-[2-Hydroxy-3-(isopropylamino)propoxy]indole;DL-LB 46;DL-Pindolol;Decreten;Durapindol;Glauco-Visken;LB 46;LB 46(pharmaceutical);N-[2-Hydroxy-3-(1H-indol-4-yloxy)propyl]-N-isopropylamine;Pectobloc;Pinbetol;Pindolol;Prinodolol;Pynastin;Visken; |
| EINECS: | 236-867-9 |
| Density: | 1.152 g/cm3 |
| Melting Point: | 167-171 °C(lit.) |
| Boiling Point: | 457.132 °C at 760 mmHg |
| Flash Point: | 230.265 °C |
| Solubility: | 0.1 M NaOH: 0.2 mg/mL |
| Appearance: | white to off-white crystalline powder |
| Hazard Symbols: |
 Xn
|
| Risk Codes: | 22-36/37/38 |
| Safety: | 26-36 |
| Transport Information: | UN 3249 |
| PSA: | 57.28000 |
| LogP: | 2.29650 |
- 144851-82-1METHYL2-AMINO-3-FLUOROBENZOATE
- 483366-12-7(2S,4R)-1-Boc-2-cyano-4-hydroxypyrrolidine
- 173606-50-3BOC-10-AMINODECANOIC ACID
- 361456-36-2METHYL (R)-(+)-ISOCYANATO-3-PHENYLPROPI&
- 5156-58-1N-(1-Benzyl-4-pipperidinyl)-N-phenylpropanamide HCl
- 81281-59-67-Benzylideneaminotheophylline
- 50288-62-5threo-Phenyl-2-piperidyl acetamide
- 82993-81-5D-threo-Ritalinic acid hydrochloride
- 47087-37-6Z-D-Glu-OMe
- 73441-42-6METHYL-5-CHLORO-2,2-DIMETHYLVALERATE
What can I do for you?
Get Best Price
Specification
The IUPAC name of Visken is 1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol. With the CAS registry number 13523-86-9 and EINECS 236-867-9, it is also named as Pindolol. The product's categories are Heterocyclic Compounds; Pindolol; Serotonin Receptor. It is white to off-white crystalline powder which is easily soluble in acetic acid, slightly soluble in methanol, insoluble in water or benzene. When heated to decomposition it emits toxic fumes of NOx.
The other characteristics of this product can be summarized as: (1)ACD/LogP: 1.97; (2)# of Rule of 5 Violations: 0; (3)ACD/LogD (pH 5.5): -1.06; (4)ACD/LogD (pH 7.4): 0.07; (5)ACD/BCF (pH 5.5): 1; (6)ACD/BCF (pH 7.4): 1; (7)ACD/KOC (pH 5.5): 1; (8)ACD/KOC (pH 7.4): 3.5; (9)#H bond acceptors: 4; (10)#H bond donors: 3; (11)#Freely Rotating Bonds: 7; (12)Polar Surface Area: 26.63 Å2; (13)Index of Refraction: 1.596; (14)Molar Refractivity: 73.41 cm3; (15)Molar Volume: 215.4 cm3; (16)Surface Tension: 47.5 dyne/cm; (17)Enthalpy of Vaporization: 75.57 kJ/mol; (18)Vapour Pressure: 3.77E-09 mmHg at 25°C; (19)Rotatable Bond Count: 6; (20)Exact Mass: 248.152478; (21)MonoIsotopic Mass: 248.152478; (22)Topological Polar Surface Area: 57.3; (23)Heavy Atom Count: 18; (24)Complexity: 248.
Preparation and Uses of Visken: It can be obtained by the amination of 4-(1,2-epoxypropoxy) indole and isopropylamine. Visken is a nonselective beta blocker with partial beta-adrenergic receptor agonist activity. What's more, it is sometimes added to a standard antidepressant therapy, if the patient fails to respond to the standard therapy alone.
When you are using this chemical, please be cautious about it as the following:
It is not only harmful if swallowed, but also irritating to eyes, respiratory system and skin. In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. If you want to contact this product, you must wear suitable protective clothing.
People can use the following data to convert to the molecule structure.
1. SMILES:OC(CNC(C)C)COc1cccc2c1ccn2
2. InChI:InChI=1/C14H20N2O2/c1-10(2)16-8-11(17)9-18-14-5-3-4-13-12(14)6-7-15-13/h3-7,10-11,15-17H,8-9H2,1-2H3
3. InChIKey:JZQKKSLKJUAGIC-UHFFFAOYAP
The following are the toxicity data which has been tested.
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| man | TDLo | oral | 71ug/kg/1D-I (0.071mg/kg) | BEHAVIORAL: TREMOR | Postgraduate Medical Journal. Vol. 56, Pg. 346, 1980. |
| mouse | LD50 | intraperitoneal | 80mg/kg (80mg/kg) | SENSE ORGANS AND SPECIAL SENSES: MYDRIASIS (PUPILLARY DILATION): EYE BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 9, Pg. 3573, 1981. |
| mouse | LD50 | intravenous | 22600ug/kg (22.6mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 28, Pg. 794, 1978. | |
| mouse | LD50 | oral | 235mg/kg (235mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) LUNGS, THORAX, OR RESPIRATION: DYSPNEA BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | Journal of Toxicological Sciences. Vol. 6, Pg. 301, 1981. |
| mouse | LD50 | subcutaneous | 336mg/kg (336mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: TREMOR BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | Niigata Igakkai Zasshi. Niigata Medical Journal. Vol. 84, Pg. 438, 1970. |
| rabbit | LD50 | intravenous | 10mg/kg (10mg/kg) | Niigata Igakkai Zasshi. Niigata Medical Journal. Vol. 84, Pg. 438, 1970. | |
| rabbit | LD50 | oral | 650mg/kg (650mg/kg) | Niigata Igakkai Zasshi. Niigata Medical Journal. Vol. 84, Pg. 438, 1970. | |
| rat | LD50 | intraperitoneal | 110mg/kg (110mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 4, Pg. 90, 1973. | |
| rat | LD50 | intravenous | 51mg/kg (51mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: ATAXIA | Niigata Igakkai Zasshi. Niigata Medical Journal. Vol. 84, Pg. 438, 1970. |
| rat | LD50 | oral | 263mg/kg (263mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: ATAXIA LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION | Niigata Igakkai Zasshi. Niigata Medical Journal. Vol. 84, Pg. 438, 1970. |
| rat | LD50 | subcutaneous | 251mg/kg (251mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: TREMOR | Niigata Igakkai Zasshi. Niigata Medical Journal. Vol. 84, Pg. 438, 1970. |
| women | TDLo | oral | 300ug/kg/3D-I (0.3mg/kg) | BEHAVIORAL: TREMOR | Postgraduate Medical Journal. Vol. 56, Pg. 346, 1980. |